Checkpoint inhibitors targeting the programmed cell death-1 (PD-1) protein and its ligand (PD-L1), known as the PDx axis, have successfully achieved responses in a number of tumor types, including hematopoietic malignancies (reviewed in [78]). This evidence concerns the gene PDCD1 and neoplasm.